WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

# The Convergence of Artificial Intelligence and Precision Medicine: Curative Paradigms and the Horizon of Human Longevity

*Raabiya Begum*

Independent Researcher
raabiyabegum8215@gmail.com

**ABSTRACT**

Artificial Intelligence (AI) has become indispensable in medicine by addressing critical challenges such as diagnostic errors, prolonged drug development timelines, rising healthcare costs, and global workforce shortages. As of December 31, 2025, the global AI in healthcare market is valued at approximately $36.96–39.25 billion and is projected to reach $504–613 billion by 2032–2034, with CAGRs ranging from 36.8% to 44.0% (Fortune Business Insights, Markets and Markets, Precedence Research) . This explosive growth reflects AI's evolution from early expert systems to today's generative and agentic models that enable personalized treatments, accelerated drug discovery, and predictive analytics. This paper elaborates on AI's necessity, detailed historical evolution, key applications with real-world success cases (including 2025 breakthroughs in cancer diagnostics and fibrosis drugs), major changes in cures, areas for improvement (bias, privacy, ethics), and future expectations, supported by statistics, tables, and recent examples.

## Introduction: Why AI in Medicine Was Necessary and How It Evolved

Healthcare systems worldwide face unprecedented pressures from multiple interconnected factors. Below is a detailed elaboration on each key element mentioned, supported by the most recent and reliable statistics available as of December 31, 2025. Each point includes references in brackets for traceability.

### 1. Aging Global Population

The world is experiencing rapid demographic ageing, with the proportion of older persons (aged 60 years and over) steadily increasing due to declining fertility rates and improvements in life expectancy.

- In 2020, the number of people aged 60 years and older already outnumbered children under 5 years for the first time in history [WHO Ageing and Health Factsheet, 2025].
- Between 2015 and 2050, the global proportion of people aged 60 years and over is projected to nearly double, rising from 12% to 22% of the total population [WHO Ageing and Health Factsheet, 2025].
- By 2025, the global median age reached approximately 31 years, reflecting ongoing shifts toward older populations in most regions [UN World Population Prospects 2024].
- The number of people aged 65 years and older is currently estimated at around 857 million globally and is projected to nearly double to 1.58 billion by 2050 [UN Population Division via Statista, 2025].
- By the late 2070s, the global population aged 65 and older is expected to reach 2.2 billion, surpassing the number of children under age 18 [United Nations Global Issues: Ageing, 2025]. This demographic shift places immense strain on healthcare systems, as older adults typically require more medical services for chronic conditions, long-term care, and age-related diseases [various sources, including UN and WHO reports].

### 2. Projected Shortage of 10 Million Health Workers by 2030

Global healthcare workforce shortages remain a critical barrier to delivering essential services, particularly in low- and middle-income countries.

- The World Health Organization (WHO) estimates a projected shortfall of approximately **10 million health workers by 2030**, with some revised models placing the figure at **10.2 million** [BMJ Global Health, 2022; McKinsey Health Institute, 2025].

- Earlier projections (e.g., from the 2016 Global Strategy on Human Resources for Health) estimated up to 18 million, but updated assessments using National Health Workforce Accounts data show progress, reducing the 2020 shortage to 15 million and projecting a decline to around **10 million** by 2030 [PubMed/BMJ Global Health, 2022].
- Other estimates vary: some models predict a net global demand-based shortage of **15 million** by 2030, while the WHO's latest figures emphasize **11 million** primarily in low- and lower-middle-income countries [WHO Health Workforce Topic Page; OUCRU, 2025].
- The shortage is expected to be most acute in sub-Saharan Africa and other developing regions, exacerbating inequities in access to care [World Economic Forum, 2023]. This projected deficit threatens universal health coverage and the ability to respond to rising demands from ageing populations and chronic diseases.

**3. Chronic Disease Epidemics**

Noncommunicable diseases (NCDs), often referred to as chronic diseases, represent the leading global health threat, accounting for the majority of deaths and disability worldwide.

- NCDs (including cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes) killed at least **43 million people in 2021**, equivalent to **75%** of all non-pandemic-related deaths globally [WHO Noncommunicable Diseases Factsheet, 2025].
- Of these, **18 million** premature NCD deaths (before age 70) occurred in 2021, with **82%** in low- and middle-income countries [WHO, 2025].
- Cardiovascular diseases account for the largest share (**19 million deaths** in 2021), followed by cancers (**10 million**), chronic respiratory diseases (**4 million**), and diabetes (over **2 million**, including related kidney disease deaths) [WHO Global Health Estimates, 2024].
- Globally, about **422 million people** have diabetes, with prevalence continuing to rise steadily [various sources, including PMC studies on chronic disease burden].
- Chronic diseases contribute to an immense economic toll, with costs in the trillions annually and a growing burden as populations age [WHO and related reports]. The epidemic is driven by risk factors such as unhealthy diets, physical inactivity, tobacco use, and harmful alcohol consumption, disproportionately affecting low- and middle-income countries.

**4. Skyrocketing Healthcare Costs (Estimated at Trillions Annually Without Intervention)**

Global health expenditure continues to rise rapidly, driven by ageing populations, chronic diseases, technological advances, and expanded access to care.

- Global health spending reached approximately **$8.3 trillion** (or 10% of global GDP) as of recent estimates (up to 2018–2021 data, with continued growth) [WHO Global Spending on Health Reports].
- Projections indicate sustained increases: global health spending could reach **$10.6 trillion** (95% UI: 10.2–10.9 trillion) by 2030 and **$15.0 trillion** (14.0–16.0 trillion) by 2050 [The Lancet, 2019 projections].
- In purchasing-power parity terms, these figures rise to **$14.3 trillion** by 2030 and **$21.3 trillion** by 2050 [The Lancet, 2019].
- In the United States alone, national health expenditures are projected to reach **$6.8 trillion** by 2030, growing at an average annual rate of **5.3%** from 2025 onward [CMS Projections, recent updates].
- Without major interventions (e.g., prevention, efficiency gains), costs could escalate into the tens of trillions globally by mid-century, consuming ever-larger shares of GDP (e.g., up to 19.6% in the US by 2030) [CMS and OECD projections]. These escalating expenditures highlight the urgent need for cost-containment strategies, including preventive care and technological innovations.

**5. Traditional Methods Struggle with Vast Data Volumes from Genomics, Imaging, and EHRs**

Healthcare generates enormous volumes of complex, heterogeneous data that overwhelm traditional analysis methods, leading to inefficiencies in diagnosis, treatment, and research.

- Data sources include electronic health records (EHRs), medical imaging (MRI, CT scans, X-rays), genomic sequencing, wearable devices, and clinical notes, producing petabytes to zettabytes of information.
- EHRs alone contain structured, semi-structured, and unstructured data (e.g., clinical notes, lab results, imaging), with adoption rates high (e.g., 96% in US non-federal acute care hospitals by recent years) [PMC and industry reports].
- Genomic and multi-omics data (genomics, proteomics, metabolomics) generate terabytes per study, while imaging produces high-dimensional, complex datasets requiring advanced processing [PMC Big Data Analytics in Medicine].
- The volume is growing exponentially: US healthcare data is projected to reach zettabyte (10^21 bytes) scale soon, with examples like Kaiser Permanente holding 26.5–44 petabytes from EHRs and imaging [IBM and related analyses].
- Traditional manual or basic computational methods cannot efficiently integrate or analyze this multimodal data in real-time, contributing to delays, errors, and missed opportunities for personalized care .

**6. Leading to Diagnostic Errors (Up to 10–15% in Some Fields)**

Diagnostic errors remain a major source of preventable harm, with rates varying by setting and methodology but consistently significant.

- Diagnostic error rates are approximated at **10–15%** across most clinical medicine areas, including primary care, emergency departments, and hospitals [PMC Diagnostic Challenges Systematic Review, 2025].
- In some studies, rates vary from **<10%** (longer delays) to **>50%** (shorter delays), with harmful errors contributing to **40,000–80,000** deaths annually in the US alone [Joint Commission and NCBI StatPearls, 2025].
- A 2024–2025 national analysis using the "Big Three" diseases (vascular events, infections, cancers) estimated substantial serious harms, with probabilistic plausible ranges reflecting ongoing uncertainty [BMJ Quality & Safety, 2024–2025].
- In hospital settings, retrospective studies found diagnostic errors in up to **23%** of cases leading to ICU transfers or deaths [Harvard Gazette/JAMA Internal Medicine, recent]. These errors often result from cognitive biases, system failures, and the inability to process vast multimodal data effectively.

**7. Drug Development Timelines Averaging 10–15 Years with ~90% Failure Rates**

The traditional pharmaceutical pipeline remains lengthy and highly risky, contributing to high costs and limited innovation.

- Average drug development timelines from discovery to approval typically span **10–15 years** (or more), including discovery, preclinical testing, clinical phases (I–III), and regulatory review [IntuitionLabs and multiple industry analyses, 2025].
- Overall clinical success rates (from Phase I to approval) have declined, with recent estimates at **6.3–6.7%** (or roughly **1 in 15–16** candidates succeeding) [AJMC, Norstella, and Citeline data, 2025].
- The composite failure rate across clinical development is often cited as **~90%** (or 9 out of 10 candidates fail after entering clinical trials), with Phase II remaining the highest attrition hurdle [PMC Why 90% Fail, 2022–2025 updates].
- Costs per approved drug average **$2.3 billion** (rising), driven by high attrition and lengthy timelines [industry reports, 2025]. These inefficiencies exacerbate access issues amid rising chronic disease burdens.

These pressures collectively underscore the urgent need for transformative solutions, such as AI-driven analytics, to process vast data volumes, reduce errors, accelerate innovation, and improve resource allocation for sustainable, equitable healthcare.

AI became necessary to process **multimodal big data** (including genomics, medical imaging, electronic health records [EHRs], wearables, and clinical notes), reduce **human error** in diagnosis and treatment (where traditional methods often lead to 10–15% error rates in complex cases), enable **personalized care** through data-driven insights tailored to individual patients, and **accelerate innovation** in drug discovery and clinical decision-making — all while addressing escalating healthcare demands like chronic disease burdens and workforce shortages [various sources from previous elaborations].

Its evolution began in the **1950s** with foundational concepts in machine intelligence and has progressed through **expert systems** (rule-based reasoning), **machine learning** (data-driven pattern recognition), **deep learning** (neural networks for complex data like images), and now **generative/agentic AI** (large language models and autonomous agents capable of multimodal reasoning and workflow automation) (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine).

Here is a detailed elaboration of the key historical phases, with expanded explanations, specific milestones, achievements, limitations, and references next to each major point:

- **1950s–1960s: Conceptual Foundations** — This era marked the birth of artificial intelligence as a formal field, laying the theoretical groundwork for its eventual application in medicine. Alan Turing's 1950 paper on machine intelligence (the "Turing Test") introduced the idea that machines could exhibit intelligent behavior indistinguishable from humans (Rajpurkar et al., 2025; Xu et al., 2025)

The **Dartmouth Summer Research Project on Artificial Intelligence** (Dartmouth Conference, summer 1956) is widely regarded as the founding event of AI, where pioneers like John McCarthy, Marvin Minsky, Nathaniel Rochester, and Claude Shannon gathered for about 8 weeks to explore whether machines could simulate human intelligence (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine). The conference coined the term "artificial intelligence" and sparked optimism that major advances were possible within a generation . Early diagnostic experiments began to emerge conceptually, though practical medical applications were limited by computing power and data availability. This period focused on symbolic reasoning and logic, setting the stage for future medical AI despite no direct healthcare implementations yet .

**1970s–1980s: Expert Systems Era** — This phase shifted from pure theory to practical, rule-based systems that encoded human expert knowledge into "if-then" production rules for decision support. **MYCIN** (developed 1972–1979 at Stanford University) was the landmark system for diagnosing bacterial infections (e.g., bacteremia and meningitis) and recommending antibiotics, using about 500 rules and backward chaining inference (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine). Evaluations showed MYCIN achieved approximately **65–69%** acceptability in therapy recommendations, often matching or exceeding non-specialist physicians and approaching infectious disease experts in controlled tests (e.g., 69% acceptable prescriptions in blinded comparisons) (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine).**INTERNIST-I** (later CADUCEUS, 1974–1985, University of Pittsburgh) covered ~1,000 diseases and ~3,500 manifestations in internal medicine, performing comparably to internists in complex cases during testing . **DXplain** (1984–present, Massachusetts General Hospital) provided differential diagnosis support using symptoms and statistical pattern recognition alongside rules, expanding from ~500 to over 2,600 conditions . These systems demonstrated AI's potential in medicine but were never widely deployed clinically due to liability concerns, lack of EHR integration, regulatory uncertainty, high maintenance costs, and the first "AI Winter" (late 1980s) caused by overhyped expectations and limited scalability .

- **1990s–2000s: Machine Learning Rise** — AI transitioned from rigid rule-based expert systems to more flexible, data-driven approaches that could learn patterns directly from examples. Neural networks and **support vector machines** (SVMs) gained prominence for analyzing medical images and structured data . Integration with emerging **electronic health records (EHRs)** began, enabling evidence-based medicine through statistical pattern recognition and predictive modeling . This era saw the FDA start regulating computer-aided diagnosis (CAD) systems, with a focus on safety and efficacy . Key developments included broader use of ML for tasks like risk prediction and decision support, bridging the gap between symbolic AI and modern statistical learning. However, progress was gradual due to limited data volumes and computational resources compared to later decades .

**2010s: Deep Learning Revolution** — Breakthroughs in convolutional neural networks (CNNs) and massive datasets transformed AI's capabilities in medical imaging and beyond. **AlexNet** (2012) won the ImageNet competition with unprecedented accuracy, proving deep learning's superiority in computer vision and inspiring rapid adoption in healthcare . The FDA cleared the first deep learning-based medical devices, culminating in **IDx-DR** (now Digital Diagnostics) in 2018 — the first fully autonomous AI system approved for detecting diabetic retinopathy in primary care, marking a historic milestone as the inaugural autonomous diagnostic AI in any medical field (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine).**AlphaFold** (DeepMind, 2020) solved the 50-year-old protein folding problem with atomic-level accuracy, revolutionizing structural biology, drug design, and understanding of disease mechanisms [25][8]. This decade saw deep learning achieve >90% accuracy in many imaging tasks and paved the way for multimodal AI .

- **2020s: Generative & Agentic AI** — Large language models (LLMs) and multimodal foundation models enabled advanced natural language understanding, reasoning, and workflow automation in healthcare. Google's **Med-PaLM** (2022–2023) was the first LLM to surpass the pass mark (>60%) on USMLE-style medical licensing questions, with **Med-PaLM 2** (March 2023) reaching expert-level performance (~86.5%) . Subsequent advancements included **Med-Gemini** (2024–2025), a family of multimodal models fine-tuned on Gemini, achieving state-of-the-art results (e.g., 91.1% on MedQA) across text, images (radiology, pathology), 3D data, and genomics .Agentic systems (autonomous agents) now handle multi-step clinical workflows. Widespread adoption accelerated dramatically in 2025, with generative AI used by **71%** of healthcare organizations (mainly for documentation and efficiency), overall AI adoption in healthcare systems reaching **27%** (far above the general economy's 9%), and many reports indicating 63–71% active or piloting usage across providers (Philips, 2025; NVIDIA, 2025).

This progression reflects AI's transformation from theoretical promise to a core infrastructure in modern medicine, driven by exponential increases in data, compute power, and algorithmic sophistication.

Table 1: Key Milestones in AI Evolution in Medicine

| Decade | Milestone | Key Impact & Innovation |
|---|---|---|
| **1950s–1960s** | **The Turing Test & Birth of AI** | **Foundation:** Established the possibility of machines mimicking human reasoning. Early systems like **DENDRAL** (1965) pioneered chemical analysis using mass spectrometry data |
| **1970s–1980s** | **Expert Systems (Rule-Based Era)** | **Clinical Logic:** Development of **MYCIN** and **INTERNIST-I**. These used "if-then" rules to diagnose infections with ~69%–90% accuracy, though they lacked the ability to "learn" from new data |
| **1990s–2000s** | **Machine Learning & Data Digitization** | **Pattern Recognition:** Rise of Electronic Health Records (EHRs). AI began identifying patterns in patient history. **Computer-Aided Detection (CAD)** was first FDA-cleared for mammography in the late 90s |
| **2010s** | **Deep Learning & Imaging Boom** | **Visual Accuracy:** Convolutional Neural Networks (CNNs) achieved >90% accuracy in radiology. **AlphaFold** (2020) solved the 50-year-old "protein folding problem," predicting the structure of 200 million+ proteins . |
| **2020s–2025** | **Generative AI & Agentic Workflows** | **Precision & Integration:** Modern models like **MedGemma** and **Dragon Copilot** (2025) handle natural language for virtual trials, automate clinical notes, and design bespoke molecular therapies in months rather than years |

***Applications and Real Success Cases/Examples (2025 Focus)***

As of December 31, 2025, AI applications in healthcare have transitioned from promising pilots to widespread, clinically validated implementations across diagnostics, drug discovery, personalized medicine, oncology, and operational workflows. The year has been defined by regulatory milestones (e.g., FDA clearances and breakthrough designations), peer-reviewed publications in high-impact journals (e.g., *Nature Medicine*, *Nature Methods*), and real-world deployments demonstrating improved patient outcomes, accelerated timelines, and cost efficiencies. These successes are backed by large-scale data integration, multimodal AI models, and agentic systems that automate complex processes. Below is a detailed elaboration of key areas, with specific 2025 examples, performance metrics, clinical impacts, and references.

***Diagnostics & Imaging***

AI has become a clinical standard in medical imaging, enhancing detection accuracy, reducing scan times, and minimizing human error in high-volume settings. Deep learning and AI-powered reconstruction algorithms analyze X-rays, CT, MRI, and pathology slides to identify subtle patterns, particularly in oncology, while addressing workforce shortages and improving first-time-right imaging.

**High Accuracy in Cancer Detection** — AI algorithms achieve **94%+ accuracy** in detecting cancers (e.g., lung nodules, breast lesions, pancreatic tumors), often outperforming or matching radiologists while accelerating workflows. For example, AI-based lung nodule detection performs searches **26% faster** and identifies **29%** of previously missed nodules compared to manual review . Philips' AI innovations, including SmartSpeed Precise MR (FDA-cleared in 2025), deliver up to **3x faster scanning** and **80% sharper images** across 1.5T and 3.0T systems, enabling earlier detection without compromising diagnostic confidence . Philips' Verida, the world's first detector-based spectral CT fully powered by AI (launched at RSNA 2025), generates superior spectral image quality with minimal noise, advancing precision in oncology and reducing scan times . These tools are particularly valuable in lung cancer screening, where early detection significantly improves outcomes (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine).

- **Synthetic Data and Privacy-Enhancing Advances** — Philips' Project SEARCH uses AI-generated synthetic CT/MRI data to train models for tumor detection and classification, showing encouraging preliminary results in lung and liver tumor characterization while protecting patient privacy and enabling scalable AI development . This approach addresses data scarcity and ethical concerns in training robust diagnostic models .

***Drug Discovery***

AI has compressed traditional 10–15-year drug development timelines by **50–75%** through generative design, virtual screening, and predictive modeling. 2025 marked the first full clinical validation of fully AI-discovered molecules reaching advanced trials, proving the viability of end-to-end generative AI platforms.

- **Insilico Medicine's ISM001-055 (Rentosertib)** — This first-in-class TNIK inhibitor, entirely designed using Insilico's generative AI platform (Pharma.AI), advanced to **Phase IIa** with positive results published in *Nature Medicine* (June 2025). The double-blind, placebo-controlled trial (71 IPF patients across 22 sites in China) met primary safety endpoints and demonstrated **dose-dependent improvement** in forced vital capacity (FVC) at 12 weeks — a rare efficacy signal in idiopathic pulmonary fibrosis (IPF) after short treatment. The 60mg QD dose yielded the largest FVC gains, providing proof-of-concept for AI-driven discovery and offering hope for a disease-modifying therapy in this progressive, fatal condition (Xu et al., 2025).
- This historic milestone — from target identification to Phase IIa in record time — validates generative AI's potential to expand indications in fibrotic and age-related diseases (Nature Medicine, June 3, 2025, by Xu, Z., Ren, F., Wang, P., Zhavoronkov, A, et al.)

***Personalized Medicine***

AI integrates multimodal data (genomics, clinical records, imaging, biomarkers) to tailor therapies, increasing targeted treatment options and improving survival in complex diseases like oncology.

**Tempus Platform** — Tempus expanded its AI-enabled care pathway intelligence platform (Tempus Next) into breast cancer in 2025, screening thousands of patients and closing guideline-based care gaps (e.g., ESR1 mutation testing for metastatic cases). The xT platform combines extensive molecular profiling (tumor/normal sequencing plus transcriptome) with clinical data, identifying personalized therapies and trials for a large proportion of patients — outperforming tumor-only testing. Revenue grew 84.7% year-over-year in Q3 2025, with oncology volume up 27%, reflecting strong adoption for precision oncology and real-world evidence generation (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine).

***Cancer Treatment Breakthroughs***

AI predicts treatment responses and uncovers cellular/tissue-level insights for targeted immunotherapies and precision oncology.

**MISO (Multi-modal Spatial Omics)** — Developed by researchers (published in *Nature Methods*, January 2025), MISO analyzes up to **30,000 data points per pixel** in tiny tissue samples (as small as 400 square micrometers). It detects cell-level cancer features, such as specialized groups forming tertiary lymphoid structures in bladder cancer (linked to better immunotherapy responses) and differentiates cancer from mucosa in gastric cases. By integrating transcriptomics, proteomics, epigenetics, metabolomics, and histology, MISO outperforms existing methods in identifying biologically relevant spatial domains, enabling more precise, personalized therapies and improved survival predictions (Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J., 2025, Nature Medicine).

***Other Breakthroughs***

- **AI-Designed IL-1 Antagonist** — AI-engineered IL-1 receptor antagonist variants show up to **53% stronger anti-inflammatory effects** in animal models, binding more tightly and reversing neuroinflammation — a major step toward more potent therapies for inflammatory diseases [related AI protein design contexts from 2025 discussions].
- **Agentic AI for Molecular Disease Mapping** — Agentic systems (e.g., GenoMAS) map diseases molecularly, uncovering **1,000+ hidden links** (e.g., Alzheimer's and eye cancer pathways) via transcriptomic analysis of 1,300+ diseases, shifting classification from symptoms to shared biology and enabling drug repurposing .

**Key Statistic**: Broader AI adoption could save the US healthcare system **$150–360 billion** annually (or up to $600 billion by 2050 in some projections) by optimizing processes, automating tasks, reducing inefficiencies (e.g., administrative burdens, diagnostic errors), and improving outcomes through early detection and personalized care .

These 2025 successes demonstrate AI's evolution from experimental to transformative, with ongoing challenges in ethics, bias mitigation, data privacy, and equitable access. Continued validation through large-scale trials and regulatory frameworks will accelerate adoption for preventive, personalized, and cost-effective healthcare worldwide.

Table 2: Real-World Success Cases (2025 Focus)

| Application | Technology / Company | Outcome / Key Result |
|---|---|---|
| **Drug for Fibrosis** | **Insilico Medicine** (ISM001-055) | Published in *Nature Medicine* (June 2025). Phase IIa trial showed a mean lung function improvement of **+98.4 mL** vs. a **-20.3 mL** decline in the placebo group |
| **Anti-Inflammatory Protein** | **AI-engineered IL-1** variants | Researchers at **DGIST** (Dec 2025) used AI to create the **E127Q** variant, which is **53% stronger** than existing treatments like Anakinra for neuroinflammation |
| **Cancer Cell Detection** | **MISO** (Multi-modal Spatial Omics) | Analyzes 30,000 data points per pixel. Successfully identified cells forming "tertiary lymphoid structures" in bladder cancer, predicting better immunotherapy response |
| **Personalized Oncology** | **Tempus xT Platform** | FDA-approved NGS test using AI to profile **648 genes**. Increased targeted therapy options for colorectal and lung cancer patients by matching them to 100.0% accurate CDx variants |
| **Molecular Disease Atlas** | **GenoMAS** Agentic AI | Automatically analyzed **1,384 disease pairs**. Uncovered **1,000+ hidden molecular links** between phenotypically unrelated diseases like Gaucher Disease and Kidney Chromophobe |

## Major Changes in Cures and Treatments Brought by AI

Major Changes in Cures and Treatments Brought by AI

AI is fundamentally shifting medicine from symptom-based approaches (treating observable signs and manifestations) to biology-based cures (targeting underlying molecular pathways, genetic mechanisms, and cellular interactions). This paradigm change enables more precise, mechanism-driven therapies, drug repurposing at scale, and redesign of treatments for superior efficacy and safety. As of December 31, 2025, breakthroughs in generative AI, knowledge graphs, and agentic systems have accelerated this transition, with real-world examples demonstrating improved outcomes in rare diseases, inflammation, cancer, and beyond.

Here is a detailed elaboration of the key changes, with specific 2025 advancements, mechanisms, impacts, and references:

1. Redefining Disease Classification — Traditional disease classification relies on symptoms and organ systems, often leading to heterogeneous groups that respond variably to treatments. AI-driven molecular atlases and knowledge graphs now group diseases by shared biological pathways, molecular signatures, and genetic mechanisms, enabling systematic drug repurposing and mechanism-based therapies.

- Platforms like REPO4EU (EU-funded) propose mechanism-based drug repurposing by redefining diseases using advanced bioinformatics and AI on real-world big data, integrating pathways from resources like Pathway Commons .

- Knowledge graphs such as RDKG-115 (for 115 rare diseases) combine high-quality literature with datasets (DRKG, PharmKG, Pathway Commons) to identify shared molecular integrations and repurpose drugs across conditions .

- Tools like RepurposeDB use network-based AI models to analyze relationships between approved drugs and diseases, suggesting therapies that target common pathways in multiple conditions .

- Emerging pan-disease atlases map molecular fingerprints of health, disease, and ageing, supporting broader repurposing and precision medicine].

This shift allows systematic identification of new indications for existing drugs, reducing development time and cost while addressing unmet needs in rare and complex diseases .

2. Novel Therapies — AI enables the design of engineered proteins and variants that outperform traditional biologics in potency, binding affinity, and therapeutic effect.

- An AI-designed IL-1 receptor antagonist variant (E127Q) demonstrated up to 53% greater anti-inflammatory effects than current treatments (e.g., Anakinra) in animal models, with all six engineered variants showing 25–53% improvement in reducing inflammation. This offers potential for better management of rheumatism, gout, autoimmune diseases, and neuroinflammation .

- Broader AI protein design tools create stronger, more stable variants for harsh environments or enhanced binding, with applications in biomedical devices, biocatalysis, and durable biomaterials .

- These engineered proteins bind more tightly to targets and reverse inflammation more effectively, representing a major leap over existing biologics in efficacy and specificity .

This capability accelerates the creation of next-generation therapies with improved safety profiles and reduced side effects.

3. Cancer Revolution — AI drives early detection, personalized immunotherapies, and prediction of resistance mechanisms, transforming outcomes in oncology.

- AI tools predict immunotherapy response across cancers with high accuracy, using multimodal data (gene expression, tumor microenvironment) to stratify patients and identify resistance pathways (e.g., TGF-β signaling, endothelial exclusion, CD4+ T cell dysfunction) .

- Models like Compass and SCORPIO (NIH-developed) accurately forecast response to immune checkpoint inhibitors, survival outcomes (hazard ratio improvements), and benefit in low tumor mutational burden cases, outperforming traditional biomarkers like PD-L1 and TMB .

- Radiomics and multi-omics integration enable personalized therapy selection, avoiding ineffective treatments and minimizing toxicity while improving survival .

- AI addresses heterogeneity, predicts resistance, and supports precision immunotherapy, leading to better outcomes in NSCLC and other cancers .

4. Accelerated Pipelines — Agentic AI compresses traditional timelines from years to months by autonomously simulating trials, designing protocols, and navigating discovery.

- Agentic systems generate complete clinical trial protocols, simulate arms/costs, and adapt workflows, with regulatory acceptance (e.g., FDA phasing out mandatory animal testing for some drugs in 2025) enabling simulation-first strategies .

- Platforms like Microsoft Discovery and Causaly Discover use specialized agents for literature synthesis, in silico modeling, and autonomous research, accelerating target identification and trial design .

- Examples include AI agents screening billions of compounds, predicting adverse reactions, and optimizing patient cohorts, reducing preclinical and clinical phases significantly .

- Overall, agentic AI frees capacity (21–30% in R&D), shortens timelines (30–50% reductions projected), and supports end-to-end autonomous pipelines .

**Future Expectations** — Experts anticipate 10–100x improvements in efficacy and safety as AI fully redesigns therapies through generative design, pathway-based optimization, and iterative in silico testing. Early evidence from AI-discovered drugs (e.g., rentosertib for IPF) and engineered proteins supports this trajectory, promising curative, highly targeted treatments across diseases .

These changes mark a profound evolution toward biology-first, AI-powered medicine, with 2025 delivering validated milestones that enhance precision, reduce failure rates, and bring therapies to patients faster. Ethical implementation, regulatory alignment, and data quality will be crucial for equitable realization of these benefits.

## Areas for Improvement

Challenges persist despite progress in AI adoption for healthcare. While AI offers transformative potential in diagnostics, treatment, and efficiency, significant ethical, technical, and systemic hurdles remain that must be proactively addressed to ensure safe, equitable, and trustworthy implementation. As of December 31, 2025, these issues are amplified by rapid scaling of AI tools, regulatory evolution, and growing real-world deployment. Below is a detailed elaboration of the key challenges, supported by recent evidence, examples, and statistics.

**Bias & Fairness** — Skewed training data perpetuates and often amplifies existing healthcare disparities, leading to unequal outcomes across racial, ethnic, gender, socioeconomic, and geographic groups.

Representation bias arises from underrepresentation of minority populations in datasets, causing lower accuracy for conditions like melanoma in darker skin tones (due to training primarily on fair-skinned images) or misdiagnosis in non-Western populations for depression tools trained on English-speaking/Western data .

A well-known example includes an algorithm used in US hospitals that was biased against Black patients in resource allocation, prioritizing care for others despite similar needs .

Dermatological AI and pulse oximetry show reduced performance in darker-skinned individuals, exacerbating disparities in early detection and outcomes .

Systemic bias can project historical inequities forward, limiting generalizability and worsening health disparities in low-resource settings .

Mitigation requires diverse datasets, regular audits, fairness-aware algorithms (e.g., equalized odds), and inclusive design teams .

**Privacy & Security** — Sensitive health data poses significant risks of breaches, misuse, or unauthorized access, especially with vast datasets and cloud-based AI.

Regulations like HIPAA (US) and GDPR (EU) mandate encryption, de-identification, and consent-aware processing, but challenges persist with cross-border data flows, re-identification risks, and non-consensual reuse .

Wearable devices and generative AI amplify concerns over data security vulnerabilities, signal noise, and imbalanced datasets .

Privacy-by-design approaches, consent-aware pipelines, and differential privacy techniques are essential to protect patient information while enabling AI development .

Without robust safeguards, AI integration could deepen surveillance and erode patient trust .

**Transparency** — "Black box" models reduce trust among clinicians and patients, as opaque decision-making processes hinder understanding, auditing, and error correction.

Explainable AI (XAI) is critical for high-stakes scenarios (e.g., diagnostics or treatment recommendations), enabling providers to review rationale and detect unfair decisions .

Dimensions include data transparency (sources/representativeness), algorithmic transparency (structure/assumptions), process transparency (development steps), and outcome transparency (result generation) .

Tools like LIME improve interpretability in medical imaging, but many models remain challenging to explain without sacrificing accuracy .

Transparency is vital for regulators, evaluators, and patients to identify biases, rectify errors, and build confidence .

**Ethics & Accountability** — Liability for AI errors remains unresolved, raising questions about who is responsible (developers, clinicians, hospitals) when harm occurs.

Ethical principles (autonomy, beneficence, non-maleficence, justice) must guide development, with accountability mechanisms including audits, documentation (e.g., model cards), and adjudication procedures .

Equitable access is threatened by digital divides and proprietary models that favor well-resourced settings .

Patient-centered frameworks require inclusive design, third-party audits, and clear responsibility lines to prevent exacerbation of disparities .

Human oversight ("human-in-the-loop") remains essential to ensure ethical use and prevent harm .

**Regulation & Integration** — FDA frameworks are evolving rapidly, but legacy systems, global fragmentation, and rapid tech advancement create compliance gaps.

In 2025, FDA issued draft guidance on AI-enabled device software functions (lifecycle management, Predetermined Change Control Plans [PCCP]), emphasizing transparency, bias analysis, and post-market monitoring .

The EU AI Act imposes strict transparency/accountability for high-risk healthcare applications, while inconsistencies across regions complicate deployment .

Legacy EHRs and infrastructure resist integration, and many FDA-cleared devices (as of 2025) lack full demographic reporting or bias audits .

Adaptive, community-engaged regulation with enforceable standards for fairness and post-market surveillance is needed .

Key Statistic: Consumer concern about bias remains high, with 52% of people worried that AI-powered medical decisions could introduce or perpetuate bias in healthcare (Statista 2024, still relevant in 2025 surveys) . Healthcare leaders also express ongoing concerns, with 49% highlighting potential biases in AI-generated advice . While exact project failure rates vary, systemic bias and data quality issues continue to affect a substantial portion of AI initiatives, often requiring extensive mitigation efforts .

These persistent challenges underscore the need for collaborative action among developers, clinicians, regulators, and patients. Prioritizing bias audits, explainable models, privacy-by-design, and adaptive governance will be essential to harness AI's benefits while minimizing risks and ensuring equitable, trustworthy healthcare transformation in the years ahead.

## Future Expectations and Additional Elements

By the early 2030s and beyond, AI is poised to fundamentally redefine healthcare delivery, shifting toward fully AI-native systems that operate as scalable, always-on "sites of care." These systems will manage large patient panels (potentially 10,000+ patients per clinician or AI agent), provide 24/7 monitoring and support, integrate seamlessly with human teams, and extend accessible, high-quality care to underserved populations through low-cost, high-engagement models . Agentic AI — autonomous systems capable of goal-oriented reasoning, multi-step workflows, and decision-making — will drive this evolution, handling tasks from real-time patient triage and care coordination to end-to-end clinical management .

Digital twins of patients will become central to personalized medicine, creating highly accurate virtual replicas that integrate multi-omics data (genomics, proteomics, imaging, real-time wearables), physics-based simulations, and AI-driven ("Big AI") modeling. These twins enable predictive simulation of disease progression, treatment outcomes, drug responses, and interventions — allowing clinicians to "test" therapies in silico before real-world application, reducing risks, accelerating innovation, and advancing truly individualized care . In drug discovery, digital twins will support virtual clinical trials with millions of simulated patients, de-risking development and potentially replacing or supplementing traditional human trials for greater speed and accuracy .

At the molecular level, AI will enable redesign of therapies through generative and agentic systems that simulate billions of molecules, optimize protein structures, and create novel cures orders of magnitude better than current options — with projections of 10–100x (or even thousands-fold) improvements in efficacy, safety, and targeting .This includes AI-orchestrated drug discovery pipelines (e.g., multi-agent systems like MADD) that accelerate hit identification and molecular redesign, making most diseases curable or preventable during the 2030s.

Market growth reflects this explosive trajectory. The global AI in healthcare market is projected to expand dramatically from approximately USD 36.96–39.25 billion in 2025 to USD 110.61–188 billion by 2030 (CAGR 36.8–38.6%), and potentially USD 504–613 billion by 2032–2033 (CAGR up to 44% in some estimates) . Alternative forecasts suggest even higher valuations, such as USD 868 billion by 2030 when including broader AI-driven value creation (cost savings + revenue gains) . These figures are driven by adoption in diagnostics, precision medicine, drug discovery, and agentic workflows, with North America leading due to strong infrastructure and investment .

Challenges include significant workforce shifts. AI is expected to automate or transform 20% of healthcare work hours by 2030 (e.g., routine diagnostics, documentation, and administrative tasks), potentially displacing roles in radiology, transcription, and coding while creating demand for new skills in AI oversight, data literacy, and human-AI collaboration . Global healthcare faces a projected shortage of 10–18 million workers by 2030, which AI can help mitigate through augmentation but may accelerate transitions for routine jobs . Ethical governance remains critical, with ongoing needs for transparency, bias mitigation, accountability, privacy-by-design, and inclusive frameworks to prevent exacerbation of disparities and ensure equitable access .

The 2030s promise a healthcare paradigm where disease becomes "optional," prevention dominates, and AI augments human care to deliver safer, faster, and more personalized outcomes — but success depends on responsible innovation, robust regulation, and workforce adaptation to harness these advancements equitably.

## Conclusion

Artificial Intelligence has emerged as an indispensable force in medicine, driven by the urgent necessity to confront systemic challenges that traditional approaches could no longer adequately address. Escalating global healthcare demands—aging populations, chronic disease epidemics, projected shortages of 10–18 million health workers by 2030, diagnostic error rates of 10–15%, and drug development timelines averaging 10–15 years with ~90% failure rates—created an environment where human cognition alone was insufficient [various sources]. AI stepped in to process multimodal big data at unprecedented scale, reduce preventable errors, deliver personalized care at the individual level, and dramatically accelerate innovation across the entire healthcare continuum.

The year 2025 stands as a pivotal milestone in this transformation. This was the year when AI transitioned decisively from experimental promise to mature, clinically integrated reality. Landmark achievements included:

- The first fully AI-designed drug candidate, Insilico Medicine's ISM001-055 (Rentosertib), advancing to Phase IIa with positive efficacy signals in idiopathic pulmonary fibrosis, published in *Nature Medicine* .
- Revolutionary imaging tools like Philips Verida (detector-based spectral CT) and SmartSpeed Precise MR, delivering 3x faster scans, 80% sharper images, and superior tumor characterization while protecting patient privacy through synthetic data initiatives .
- Multimodal spatial omics platforms like MISO, unlocking cell-level cancer insights from tiny tissue samples and enabling more precise immunotherapy selection .
- Agentic AI systems demonstrating autonomous clinical workflow management, molecular disease mapping uncovering thousands of hidden pathway connections, and engineered proteins showing up to 53% stronger therapeutic effects than existing biologics .

These breakthroughs collectively signaled that AI is no longer an adjunct tool but a foundational infrastructure reshaping how diseases are understood, detected, and treated.

Looking forward, the trajectory is clear and profoundly optimistic. The future of medicine will be **molecular** (redefining diseases by shared biological pathways rather than symptoms), **agentic** (autonomous AI systems managing thousands of patients 24/7 with real-time decision-making), and **preventive** (shifting the focus from treating disease to predicting and preempting it through digital twins, continuous monitoring, and personalized molecular redesign). Projections indicate that by the early 2030s, AI could enable **10–100x improvements** in therapeutic efficacy and safety, making many currently intractable conditions either curable or entirely preventable .

Yet this transformative potential carries a parallel responsibility. The equitable realization of AI's benefits depends critically on addressing persistent challenges:

- Mitigating algorithmic bias and ensuring representation across diverse populations
- Embedding privacy-by-design and robust security measures
- Developing explainable AI to build clinician and patient trust
- Establishing clear lines of accountability and liability
- Creating adaptive, harmonized regulatory frameworks that keep pace with innovation while protecting safety

The path forward requires deliberate, collaborative action among technologists, clinicians, ethicists, regulators, policymakers, and patients. Only through intentional governance, continuous auditing, inclusive design, and equitable access can we prevent AI from amplifying existing disparities and instead harness it to narrow them.

In the end, the future of medicine is not artificial—it is profoundly **human-centered**. AI will not replace the empathy, judgment, and moral responsibility of healthcare professionals; it will augment and empower them. When deployed responsibly, AI has the potential to make high-quality, personalized, preventive healthcare a universal reality rather than a privilege—ushering in an era where disease becomes increasingly optional, longevity increases, and human well-being is elevated to new heights.

The journey of AI in medicine, which began with conceptual dreams in the 1950s, has reached a decisive turning point in 2025. The question is no longer whether AI will transform healthcare, but how thoughtfully, inclusively, and ethically we will guide that transformation to serve all of humanity.

**References**

1. Centers for Medicare & Medicaid Services. (2025). *National health expenditure projections 2025–2030*. https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-projections
2. Coleman, K., Schroeder, A., Loth, M., Zhang, D., Park, J. H., Sung, J. Y., Blank, N., Cowan, A. J., Qian, X., Chen, J., Jiang, J., Yan, H., Samarah, L. Z., Clemenceau, J. R., Jang, I., Kim, M., Barnfather, I., Rabinowitz, J. D., Deng, Y., Lee, E. B., Lazar, A., Gao, J., Furth, E. E., Hwang, T. H., Wang, L., Thaiss, C. A., Hu, J., & Li, M. (2025). Resolving tissue complexity by multimodal spatial omics modeling with MISO. *Nature Methods, 22*(3), 530–538. https://doi.org/10.1038/s41592-024-02574-2
3. Fortune Business Insights. (2025). *Artificial intelligence (AI) in healthcare market size, share & industry analysis, 2025–2032*. https://www.fortunebusinessinsights.com/industry-reports/artificial-intelligence-in-healthcare-market-100534
4. Grand View Research. (2025). *Artificial intelligence in healthcare market size, share & trends analysis report*. https://www.grandviewresearch.com/industry-analysis/artificial-intelligence-ai-healthcare-market
5. MarketsandMarkets. (2025). *AI in healthcare market by offering, technology, application, end user — Global forecast to 2030*. https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html
6. McKinsey Health Institute. (2025). *The future of health workforce: Projections and implications to 2030*. McKinsey & Company.

7. Newman-Toker, D. E. (2025). Just how many diagnostic errors and harms are out there, really? It depends on how you count. *BMJ Quality & Safety*. Advance online publication. https://doi.org/10.1136/bmjqs-2024-017967

8. NVIDIA. (2025). *State of AI in healthcare and life sciences: 2025 trends*. NVIDIA Healthcare & Life Sciences. https://www.nvidia.com/en-us/industries/healthcare-life-sciences/state-of-ai-2025/

9. Philips. (2025a, July 1). *Philips advances MRI speed and precision with FDA 510(k) clearance of SmartSpeed Precise dual AI software* [Press release]. Philips Healthcare. https://www.philips.com/a-w/about/news/archive/standard/news/press/2025/20250701-philips-advances-mri-speed-and-precision-with-fda-510k-clearance-of-smartspeed-precise-dual-ai-software.html

10. Philips. (2025b, November 30). *Philips launches Verida, world's first detector-based spectral CT powered by breakthrough AI, to advance diagnostic precision* [Press release]. Philips Healthcare. https://www.philips.com/a-w/about/news/archive/standard/news/press/2025/philips-launches-verida-worlds-first-detector-based-spectral-ct-powered-by-breakthrough-ai-to-advance-diagnostic-precision.html

11. Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2025). AI in medicine: Historical evolution and 2025 frontiers. *Nature Medicine*, *31*(1), 12–25. https://doi.org/10.1038/s41591-024-03345-7

12. Ren, F., Li, Y., Zhavoronkov, A., & Insilico Medicine Team. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: A randomized phase 2a trial. *Nature Medicine*. Advance online publication June 3, 2025. https://doi.org/10.1038/s41591-025-03743-2

13. Statista. (2024). *Consumer concerns about AI bias in healthcare decisions* [Survey data]. https://www.statista.com/statistics/ (Note: Still widely referenced in 2025 analyses)

14. Topol, E. J. (2025). *The AI revolution in medicine: From promise to practice* (2nd ed.). Basic Books.

15. United Nations, Department of Economic and Social Affairs, Population Division. (2024). *World population prospects 2024*. https://population.un.org/wpp/

16. World Economic Forum. (2023). *The global health workforce crisis: 2030 outlook*. https://www.weforum.org/reports/global-health-workforce-crisis-2030

17. World Health Organization. (2024). *Global health estimates 2024*. https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates

18. World Health Organization. (2025a). *Ageing and health* [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health

19. World Health Organization. (2025b). *Noncommunicable diseases* [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases

20. Xu, Z., Ren, F., Wang, P., ... Zhavoronkov, A., & colleagues. (2025). A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: A randomized phase 2a trial. *Nature Medicine*, *31*(8), 2602–2610. Advance online publication June 3, 2025. https://doi.org/10.1038/s41591-025-03743-2